B38.0 Acute pulmonary coccidioidomycosis

Name of the Condition

• Acute pulmonary coccidioidomycosis

Summary

Acute pulmonary coccidioidomycosis is a fungal infection of the lungs caused by Coccidioides species. It typically presents as a mild to moderate respiratory illness, though severe disease can occur, especially in individuals with weakened immune systems. The condition is part of the broader coccidioidomycosis spectrum and is characterized by acute onset of symptoms following exposure to airborne fungal spores.

Causes

The infection results from inhaling airborne spores of Coccidioides fungi, which are endemic to arid regions such as the southwestern United States, Mexico, and parts of Central and South America. These spores are released from soil and can become airborne during activities that disturb the ground, including construction, farming, or windstorms.

Risk Factors

• Residence or travel to endemic regions, particularly during dry, dusty seasons.
• Occupational exposure to soil (e.g., farmers, construction workers, archaeologists).
• Immunocompromised states, including HIV/AIDS, organ transplantation, or prolonged corticosteroid use.
• Pregnancy, especially the third trimester.
• Advanced age.

Symptoms

• Fatigue and malaise.
• Cough, chest pain, or shortness of breath.
• Fever, night sweats, or weight loss.
• Joint pain or skin rash (erythema nodosum).
• Severe cases may involve respiratory distress or disseminated infection.

Diagnosis

Diagnosis is based on clinical evaluation, imaging (e.g., chest X-rays or CT scans), and laboratory testing. Common tests include sputum cultures, serologic assays for Coccidioides antibodies, or antigen detection. Histopathologic examination of tissue samples may be used in complex cases. A definitive diagnosis requires confirmation of Coccidioides infection through laboratory methods.

Treatment Options

Mild cases may resolve without specific antifungal therapy. Moderate to severe infections typically require antifungal medications, such as fluconazole or amphotericin B. Treatment duration varies based on disease severity and patient response. Immunocompromised individuals often need prolonged therapy to prevent relapse.

Prognosis and Follow-Up

Most healthy individuals recover fully with appropriate treatment. However, immunocompromised patients or those with severe disease may experience prolonged recovery or complications. Follow-up care includes monitoring for symptom resolution, repeat imaging if needed, and assessing for signs of dissemination. Long-term surveillance may be necessary for high-risk groups.

Complications

• Chronic pulmonary coccidioidomycosis (persistent lung infection).
• Disseminated disease affecting other organs (e.g., skin, bones, central nervous system).
• Respiratory failure in severe cases.
• Meningitis or other central nervous system involvement.

Lifestyle & Prevention

• Avoiding activities that stir up dust in endemic areas (e.g., during construction or farming).
• Using respiratory protection (e.g., masks) in high-risk environments.
• Staying informed about local outbreaks or endemic regions when traveling.
• Maintaining overall health to support immune function.

When to Seek Professional Help

Seek medical attention if you experience persistent respiratory symptoms (e.g., cough, chest pain, shortness of breath), especially after travel to or residence in an endemic region. Prompt evaluation is critical for immunocompromised individuals or those with severe symptoms, as early treatment improves outcomes.

Tips for Medical Coders

Document the diagnosis of acute pulmonary coccidioidomycosis with code B38.0. Ensure clinical documentation supports the acute nature of the infection and its pulmonary involvement. Include details such as symptom onset, exposure history, and any diagnostic test results to validate the code assignment. Note that this code is specific to acute pulmonary disease and should not be used for chronic or disseminated forms.